Fernö M, Borg A
Anticancer Res. 1985 May-Jun;5(3):307-12.
Specific binding sites for the antiestrogen tamoxifen (AEBStot), as measured with the dextran-coated charcoal technique and Scatchard analysis, were quantitated in 43 of 44 breast cancer samples (41-2,100 fmol/mg protein). In this work, AEBStot has been defined as the sum of AEBSspec and estrogen receptor (ER), AEBSspec shows a very weak positive correlation with ER, and no correlation with progesterone receptor. Tamoxifen (TAM) has a lower affinity to ER compared with one of its main metabolites, 4-OH-TAM. This may be one reason why inhibition by excess estradiol on 3H-4-OH-TAM binding was better correlated with ER content in the same sample than if 3H-TAM was the radioactive ligand. It is therefore suggested that 3H-4-OH-TAM is a better choice than 3H-TAM for measuring AEBSspec alone. A possible role of AEBSspec for the clinical effects of TAM is discussed.
采用葡聚糖包被活性炭技术和Scatchard分析测定,44例乳腺癌样本中有43例(41 - 2,100 fmol/mg蛋白)检测到抗雌激素他莫昔芬的特异性结合位点(总AEBS)。在本研究中,总AEBS被定义为特异性AEBS和雌激素受体(ER)之和,特异性AEBS与ER呈非常弱的正相关,与孕激素受体无相关性。与它的主要代谢产物之一4-羟基他莫昔芬相比,他莫昔芬(TAM)对ER的亲和力较低。这可能是为什么在同一样本中,过量雌二醇对3H-4-羟基他莫昔芬结合的抑制作用比以3H-TAM作为放射性配体时与ER含量的相关性更好的原因之一。因此,建议仅测定特异性AEBS时,3H-4-羟基他莫昔芬比3H-TAM是更好的选择。文中讨论了特异性AEBS对他莫昔芬临床疗效的可能作用。